The application of hazard analysis and critical control points and risk management in the preparation of anti-cancer drugs

International Journal for Quality in Health Care

Volumn 21, Issue 1, 2009, Pages 44-50

  Bonan, Brigitte ^a   Martelli, Nicolas ^a   Berhoune, Malik ^a   Maestroni, Marie Laure ^a   Havard, Laurent ^a   Prognon, Patrice ^a  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Anti cancer drugs; Hazard Analysis and Critical Control Points method; Quality management; Risk management

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; CANCER CHEMOTHERAPY; DISEASE SEVERITY; DRUG CONTAMINATION; DRUG PACKAGING; DRUG SYNTHESIS; FOLLOW UP; HAZARD ASSESSMENT; HUMAN; MICROBIAL CONTAMINATION; MONITORING; PHARMACIST; PHARMACY; PRESCRIPTION; PRIORITY JOURNAL; QUALITY CONTROL; RISK MANAGEMENT; SAFETY;

ANTINEOPLASTIC AGENTS; DRUG COMPOUNDING; HUMANS; INTERDISCIPLINARY COMMUNICATION; RISK MANAGEMENT; SAFETY MANAGEMENT;

EID: 58849149432     PISSN: 13534505     EISSN: 14643677     Source Type: Journal    
DOI: 10.1093/intqhc/mzn052     Document Type: Article

References (29)

1. Crauste-Manciet S, Sessink PJ, Ferrari S et al. Environmental contamination with cytotoxic drugs in healthcare using positive air pressure isolators. Ann Occup Hyg 2005;49:619-28.
2. Sessink PJ, Wittenhorst BC, Anzion RB et al. Exposure of pharmacy technicians to antineoplastic agents: Reevaluation after additional protective measures. Arch Environ Health 1997;52:240-4.
3. Sessink PJ, Timmersmans JL, Anzion RB et al. Assessment of occupational exposure of pharmaceutical plant workers to 5-fluorouracil. Determination of alpha-fluoro-beta-alanine in urine. J Occup Med 1994;36:79-83.
4. Pethran A, Schierl R, Hauff K et al. Uptake of antineoplastic agents in pharmacy and hospital personnel. Part I: Monitoring of urinary concentrations. Int Arch Occup Environ Health 2003;76:5-10.
5. Rajan-Sithamparanadarajah R, Roff M, Delgado P et al. Patterns of dermal exposure to hazardous substances in European union workplaces. Ann Occup Hyg 2004;48:285-97.
6. Mason HJ, Morton J, Garfitt SJ et al. Cytotoxic drug contamination on the outside of vials delivered to a hospital pharmacy. Ann Occup Hyg 2003;47:681-5.
7. Sessink PJ, Bos RP. Drugs hazardous to healthcare workers. Evaluation of methods for monitoring occupational exposure to cytostatic drugs. Drug Saf 1999;20:347-59.
8. Sorsa M, Anderson D. Monitoring of occupational exposure to cytostatic anticancer agents. Mutat Res 1996;355:253-61.
9. Descoutures JM. Preparation of antineoplastic agents (in French). Ann Pharm Fr 2006;64:7-16.
10. Cazin JL, Gosselin P. Implementing a multiple-isolator unit for centralized preparation of cytotoxic drugs in a cancer center pharmacy. Pharm World Sci 1999;21:177-83.
11. Mason HJ, Blair S, Sams C et al. Exposure to antineoplastic drugs in two UK hospital pharmacy units. Ann Occup Hyg 2005;49 603-10.
12. ASHP. Guidelines on Handling Hazardous Drugs. Am J Health Syst Pharm 2006;63:1172-91.
13. Good Manufacturing Practices (in French). Agence Française de Sécurité Sanitaire et des Produits de Santé 2000.
14. Good Preparations Practices (in French). Agence Française de Sécurité Sanitaire et des Produits de Santé 2007.
15. Jahnke M, Kuhn KD. Use of the hazard analysis and critical control points (HACCP) risk assessment on a medical device for parenteral application. PDA J Pharm Sci Technol 2003;57:32-42.
16. Panunzio MF, Antoniciello A, Pisano A et al. Evaluation of HACCP plans of food industries: Case study conducted by the Servizio di Igiene degli Alimenti e della Nutrizione (Food and Nutrition Health Service) of the local health authority of Foggia, Italy. Int J Environ Res Public Health 2007;4:228-32.
17. WHO Expert Committee on specifications for pharmaceutical preparations. World Health Organ Tech Rep Ser 1996;863:1-194.
18. Hulebak KL, Schlosser W. Hazard analysis and critical control point (HACCP) history and conceptual overview. Risk Anal 2002;22 547-52.
19. Controls, Studies and Formation for Food Quality Improvement, CEFAQ (10 August 2008, http://www.cefaq.fr/ date last accessed).
20. Hyman WA. The Application of HACCP in Clinical Engineering. J Clin Eng 2003;28:158-62.
21. Bonnabry P, Cingria L, Ackermann M et al. Use of a prospective risk analysis method to improve the safety of the cancer chemotherapy process. Int J Qual Health Care 2006;18:9-16.
22. Swanson KM, Anderson JE. Industry perspectives on the use of microbial data for hazard analysis and critical control point validation and verification. J Food Prot 2000;63:815-8.
23. Ljungqvist B, Reinmuller B. Hazard analyses of airborne contamination in clean rooms - application of a method for limitation of risks. PDA J Pharm Sci Technol 1995;49:239-43.
24. Havard L, Bonan B, Huen JM et al. Quality control in centralised cytotoxic reconstitution unit: Dream or reality? STP Pharma Pratiques 2005;15:148-60.
25. Massoomi FF, Neff B, Pick A et al. Implementation of a safety program for handling hazardous drugs in a community hospital. Am J Health Syst Pharm 2008;65:861-5.
26. Polovich M. Safe handling of hazardous drugs. Online J Issues Nurs 2004;9:6.
27. Peters BG, Wilson AL, Lunik MC et al. Certification program in antineoplastic drug preparation for pharmacy technicians and pharmacists. Am J Hosp Pharm 1994;51:1902-6.
28. Maragakis LL, Bradley KL, Song X et al. Increased catheterrelated bloodstream infection rates after the introduction of a new mechanical valve intravenous access port. Infect Control Hosp Epidemiol 2006;27:67-70.
29. Slama C, Jerome J, Jacquot C et al. Prescription errors with cytotoxic drugs and the inadequacy of existing classifications. Pharm World Sci 2005;27:339-43.